There are useful Clinical Guidelines for GPs on management of common biochemistry problems on the NBT website including:
Hypercalcaemia
Hyperkalaemia
Hyperlipidaemia
Hypoglycaemia
Hyponatraemia
Proteinuria
The Clinical Biochemistry department at UHBW provides a comprehensive service to UHBW and surrounding GPs.
The service can be used to:
Discuss biochemical results with a consultant
Agree next steps, e.g. add-on tests to existing samples
Discuss potential referrals to the Pathology Day Unit, e.g. for blood transfusion, iron transfusion, water deprivation test, endocrine dynamic function tests, etc.
During working hours (Mon - Fri, 9am - 5pm) advice on the appropriateness and interpretation of tests and adding on tests can be obtained from the Duty Biochemist:
Out of hours the department can be contacted via the BRI switchboard 0117 923 0000. For the laboratory ask for bleep 2331. For urgent clinical advice ask for the on-call Biochemist.
Please see the specific Pathology Remedy page.
The Clinical Biochemistry Department at NBT provides a comprehensive, clinically led laboratory service for North Bristol NHS Trust and the surrounding community.
Information about specimen requirements for biochemistry tests, endocrinology investigation protocols and interpretation advice is available here.
The duty biochemist can be contacted as below:
Telephone : 0117 4148437
Email: nbn-tr.ClinicalBiochemistryNBT@nhs.net
Biotin at doses of >5 mg per day (higher than average in the body) may interfere in the Beckman immunoassays for CA199, free T3 and free T4 in use at UHBW, NBT and RUH, causing false high or low results. Such doses are only present in over-the-counter high dose biotin supplements or high dose treatment regimens. Multivitamin tablets contain much lower amounts of biotin and pose no risk of interference.
For more details please see here, or contact the BRI duty biochemist on 0117 342 7834.
Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.